Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitud...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Livnat, Raposo, Catarina, Rechtman, Ariel, Zveik, Omri, Levin, Netta, Oiknine‐Djian, Esther, Wolf, Dana G., Vaknin‐Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082479/
https://www.ncbi.nlm.nih.gov/pubmed/35243687
http://dx.doi.org/10.1002/ana.26343
Descripción
Sumario:The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS‐CoV‐2 mRNA vaccine in ocrelizumab‐treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab‐treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800

Ejemplares similares